Skip to main content
Clinical Trials/ACTRN12620000991910
ACTRN12620000991910
Terminated
未知

Double-blind, placebo-controlled, cross-over trial of LivauxTM for the treatment of constipation and microbiome restoration in Parkinson’s disease.

The University of Queensland0 sites14 target enrollmentOctober 1, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Parkinson's Disease
Sponsor
The University of Queensland
Enrollment
14
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2020
End Date
September 13, 2022
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Diagnosis of Parkinson’s disease according to UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria
  • 2\.Currently meet ROME IV criteria for functional constipation
  • 3\.Experience 3 or fewer bowel motion days per week
  • 4\.18 years or older
  • 5\.BMI range 19\-35
  • 6\.Prepared to maintain current dietary habits for the duration of the study

Exclusion Criteria

  • 1\.Allergy to Kiwifruit
  • 2\.Allergy to latex
  • 3\.Clinically significant (as defined by local PI) gastrointestinal disorders not limited to:
  • Inflammatory Bowel Disease
  • History of major GI surgery
  • Structural or metabolic diseases affecting GI system
  • 4\.Other identifiable cause of constipation such as other neurological diseases, peripheral neuropathy, iatragenic constipation
  • 5\.Clinically significant or respiratory, cardiac failure or other concurrent medical conditions as defined by local PI
  • 6\.Current or recent use (within 2 weeks of baseline) of probiotics including
  • Probiotic yoghurt or probiotic yoghurt drinks,

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A double-blind, placebo-controlled crossover trial to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal - Sibutramine effects on energy balance in obesityObesity defined as BMI > 30 kg /m2Classification code 10029883
EUCTR2005-002080-88-GBAintree Hospitals NHS Trust and University of Liverpool36
Completed
Not Applicable
Double-blind, placebo-controlled crossover trial of inhaled oxygen in the treatment of acute cluster headacheCluster headacheNervous System Diseases
ISRCTN94092997BOC Ltd (UK)55
Active, not recruiting
Not Applicable
A double-blind, randomized, cross-over, placebocontrolled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic doses of inhaled QAB149 and salmeterol - NDCOPDMedDRA version: 6.1Level: PTClassification code 10009026
EUCTR2007-001051-19-ITOVARTIS FARMA24
Active, not recruiting
Not Applicable
Double-blind, placebo controlled cross-over study to assess efficacy of Levetiracetam in paediatric and childhood Tourette syndrome. Estudio cruzado, aleatorizado, doble ciego controlado con placebo, para evaluar la eficacia del Levetiracetam en el control de los tics de pacientes pediátricos y adolescentes con síndrome de Gilles de la Tourette
EUCTR2005-002041-40-ESHospital Sant Joan de Déu
Active, not recruiting
Not Applicable
Double-blind, placebo controlled cross-over study to assess the efficacy of Levetiracetam in paediatric and childhood non-epileptic myoclonusEstudio cruzado, aleatorizado, doble ciego controlado con placebo, para evaluar la eficacia del Levetiracetam en el tratamiento del mioclonus no epiléctico en pacientes pediátricos y adolescentes
EUCTR2005-002042-19-ESHospital Sant Joan de Déu